ASTHMA
MCID: AST005
MIFTS: 82

Asthma (ASTHMA)

Categories: Genetic diseases, Immune diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Asthma

MalaCards integrated aliases for Asthma:

Name: Asthma 57 38 12 76 53 75 75 37 29 55 6 43 3 44 15 63 63 73
Asthma, Susceptibility to 57 29 6 40
Asthma, Diminished Response to Antileukotriene Treatment in 57 13 6
Chronic Obstructive Asthma 12 55 73
Bronchial Hyperreactivity 12 55 73
Asthma, Nocturnal, Susceptibility to 57 6
Asthma, Protection Against 57 6
Chronic Obstructive Asthma with Acute Exacerbation 12
Chronic Obstructive Asthma with Status Asthmaticus 12
Asthma-Related Traits, Susceptibility to 57
Asthma, Exercise-Induced 73
Exercise Induced Asthma 12
Exercise-Induced Asthma 12
Asthma Exercise-Induced 55
Asthma-Related Traits 57
Asthma, Bronchial 57
Asthma, Nocturnal 57
Bronchial Asthma 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant vs. multifactorial


Classifications:



External Ids:

OMIM 57 600807
Disease Ontology 12 DOID:2841
ICD9CM 35 493 493.9
MeSH 44 D001249
NCIt 50 C28397
SNOMED-CT 68 21341004
KEGG 37 H00079
SNOMED-CT via HPO 69 195967001 991000119106

Summaries for Asthma

MedlinePlus : 43 Asthma is a chronic disease that affects your airways. Your airways are tubes that carry air in and out of your lungs. If you have asthma, the inside walls of your airways become sore and swollen. That makes them very sensitive, and they may react strongly to things that you are allergic to or find irritating. When your airways react, they get narrower and your lungs get less air. Symptoms of asthma include Wheezing Coughing, especially early in the morning or at night Chest tightness Shortness of breath Not all people who have asthma have these symptoms. Having these symptoms doesn't always mean that you have asthma. Your doctor will diagnose asthma based on lung function tests, your medical history, and a physical exam. You may also have allergy tests. When your asthma symptoms become worse than usual, it's called an asthma attack. Severe asthma attacks may require emergency care, and they can be fatal. Asthma is treated with two kinds of medicines: quick-relief medicines to stop asthma symptoms and long-term control medicines to prevent symptoms. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Asthma, also known as asthma, susceptibility to, is related to allergic asthma and intrinsic asthma, and has symptoms including coughing, shortness of breath and recurring periods of wheezing (a whistling sound while breathing). An important gene associated with Asthma is ADRB2 (Adrenoceptor Beta 2), and among its related pathways/superpathways are Asthma and Cytokine Signaling in Immune system. The drugs Accolate and Advair have been mentioned in the context of this disorder. Affiliated tissues include Lung, lung and testes, and related phenotypes are asthma and immune system

Disease Ontology : 12 A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors. The disease has symptom recurring periods of wheezing (a whistling sound while breathing), has symptom chest tightness, has symptom shortness of breath, has symptom mucus production and has symptom coughing. The symptoms appear due to a variety of triggers such as allergens, irritants, respiratory infections, weather changes, exercise, stress, reflux disease, medications, foods and emotional anxiety.

NIH Rare Diseases : 53 Asthma is a breathing disorder that affects the airways. People with this condition experience recurrent swelling and narrowing of the airways of the lungs which is associated with wheezing, shortness of breath, chest tightness, and coughing. Most affected people have episodes of symptoms ("asthma attacks") followed by symptom-free periods; however, some may experience persistent shortness of breath in between attacks. Asthma is considered a complex or multifactorial condition that is likely due to a combination of multiple genetic, environmental, and lifestyle factors. Many people with asthma have a personal or family history of allergies, such as hay fever or eczema. Having a family member with asthma is associated with an increased risk of developing the condition. Treatment generally includes various medications, both to prevent asthma attacks and to provide quick relief during an attack.

OMIM : 57 Bronchial asthma is the most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. Asthma-related traits include clinical symptoms of asthma, such as coughing, wheezing, and dyspnea; bronchial hyperresponsiveness (BHR) as assessed by methacholine challenge test; serum IgE levels; atopy; and atopic dermatitis (Laitinen et al., 2001; Illig and Wjst, 2002; Pillai et al., 2006). See 147050 for information on the asthma-associated phenotype atopy. (600807)

CDC : 3 Asthma is a disease that affects your lungs. It causes repeated episodes of wheezing, breathlessness, chest tightness, and nighttime or early morning coughing. Asthma can be controlled by taking medicine and avoiding the triggers that can cause an attack. You must also remove the triggers in your environment that can make your asthma worse.

Novus Biologicals : 56 Asthma is a chronic lung disease that causes inflammation, thickening and narrowing of airways, as well as an overproduction of mucus. More than 300 million people worldwide suffer from asthma. Asthma symptoms include wheezing, shortness of breath, coughing and tightness of the chest. Interleukin 13 (IL-13) is the key effector cytokine in asthma. IL-13 stimulates airway fibrosis via action of matrix metalloproteinases (MMPs) on tumor transforming growth factor beta (TGN-beta), and also promotes epithelial damage, mucus production and an increased concentration of eosinophils. The inflammatory response characteristic of asthma is augmented by the production of IL-13 and other TH2 cytokines.

UniProtKB/Swiss-Prot : 75 Asthma: The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with wheezing due to spasmodic contraction of the bronchi.

PubMed Health : 63 About asthma: Asthma (AZ-ma) is a chronic (long-term) lung disease that inflames and narrows the airways. Asthma causes recurring periods of wheezing (a whistling sound when you breathe), chest tightness, shortness of breath, and coughing. The coughing often occurs at night or early in the morning.Asthma affects people of all ages, but it most often starts during childhood. In the United States, more than 25 million people are known to have asthma. About 7 million of these people are children.

Wikipedia : 76 Asthma is a common long-term inflammatory disease of the airways of the lungs. It is characterized by... more...

Related Diseases for Asthma

Diseases related to Asthma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 670)
# Related Disease Score Top Affiliating Genes
1 allergic asthma 34.9 CCL11 IL13 IL4R IL5 NPSR1 RNASE3
2 intrinsic asthma 34.2 IL5 RNASE3
3 cough variant asthma 34.1 IL5 RNASE3
4 status asthmaticus 33.6 ADRB2 IL5 RNASE3
5 ige responsiveness, atopic 33.5 ADRB2 IL13 IL4R IL5 PLA2G7 RNASE3
6 allergic rhinitis 33.3 ALOX5 CCL11 IL13 IL4R IL5 RNASE3
7 pollen allergy 32.9 ADRB2 IL13 IL4R IL5 RNASE3
8 dermatitis 32.9 CCL11 IL13 IL5 NPSR1
9 dermatitis, atopic 32.9 CCL11 CYSLTR1 IL13 IL4R IL5 RNASE3
10 lung disease 32.7 ADRB2 IL13 IL5 RNASE3 TNF
11 allergic hypersensitivity disease 32.7 CCL11 IL13 IL4R IL5 RNASE3
12 churg-strauss syndrome 32.6 IL5 RNASE3 TNF
13 latex allergy 32.6 IL13 IL5 RNASE3
14 chronic eosinophilic pneumonia 32.6 CCL11 IL5 RNASE3
15 esophagitis, eosinophilic, 1 32.6 CCL11 IL13 IL5
16 rhinitis 32.2 CCL11 CYSLTR1 IL13 IL4R IL5 RNASE3
17 immune system disease 32.0 IL13 IL5 TNF
18 pulmonary disease, chronic obstructive 31.9 ADRB2 CCL11 IL13 RNASE3 TNF
19 bronchitis 31.7 CCL11 IL5 RNASE3 TNF
20 bronchiolitis 31.6 CCL11 IL13 IL4R IL5 RNASE3 TNF
21 hypereosinophilic syndrome 31.3 CCL11 IL13 IL5 RNASE3
22 food allergy 31.3 IL13 IL5 RNASE3
23 pneumonia 31.2 CCL11 IL13 IL5 TNF
24 respiratory allergy 31.2 CCL11 IL13 IL4R IL5 RNASE3
25 sinusitis 31.1 CYSLTR1 IL4R IL5 RNASE3
26 pulmonary eosinophilia 31.1 CCL11 IL13 IL5 RNASE3
27 conjunctivitis 30.9 CCL11 IL13 IL5 RNASE3
28 common cold 30.9 CCL11 IL13 IL5 RNASE3
29 eosinophilic pneumonia 30.8 CCL11 IL13 IL5 RNASE3
30 esophagitis 30.8 CCL11 IL13 IL5
31 otitis media 30.6 CCL11 RNASE3 TNF
32 gastroenteritis 30.6 CCL11 IL5 RNASE3 TNF
33 eosinophilic gastroenteritis 30.6 CCL11 IL5 RNASE3
34 allergic conjunctivitis 30.6 CCL11 IL13 IL5 RNASE3
35 inflammatory bowel disease 30.6 ALOX5 CCL11 IL13 IL4R IL5 NPSR1
36 strongyloidiasis 30.6 CCL11 IL13 IL5
37 schistosomiasis 30.5 IL13 IL5 RNASE3 TNF
38 respiratory syncytial virus infectious disease 30.4 IL13 IL5
39 keratoconjunctivitis 30.3 CCL11 IL13 IL5 RNASE3 TNF
40 vernal keratoconjunctivitis 30.3 CCL11 IL13 IL5 RNASE3
41 bronchial disease 30.2 ADRB2 ALOX5 CCL11 CYSLTR1 IL13 IL5
42 chronic conjunctivitis 30.1 CCL11 IL13 IL5 RNASE3
43 drug allergy 30.0 IL4R IL5
44 paranasal sinus disease 30.0 ALOX5 IL13 IL5
45 asthma, nasal polyps, and aspirin intolerance 12.6
46 asthma-related traits 1 12.5
47 asthma-related traits 2 12.5
48 asthma-related traits 4 12.4
49 asthma-related traits 5 12.4
50 asthma-related traits 7 12.4

Comorbidity relations with Asthma via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Osteoporosis
Respiratory Failure Status Asthmaticus

Graphical network of the top 20 diseases related to Asthma:



Diseases related to Asthma

Symptoms & Phenotypes for Asthma

Symptoms via clinical synopsis from OMIM:

57
Resp:
asthma
airway hyperresponsiveness


Clinical features from OMIM:

600807

Symptoms:

12
  • coughing
  • shortness of breath
  • recurring periods of wheezing (a whistling sound while breathing)
  • chest tightness
  • mucus production

Human phenotypes related to Asthma:

32
# Description HPO Frequency HPO Source Accession
1 asthma 32 HP:0002099

UMLS symptoms related to Asthma:


dyspnea, cyanosis, wheezing, snoring, coughing, sneezing, spasm, expiratory wheeze, labored breathing

MGI Mouse Phenotypes related to Asthma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.7 ADRB2 ALOX5 CCL11 CYSLTR1 HLA-G IL13
2 respiratory system MP:0005388 9.17 CCL11 CYSLTR1 IL13 IL4R IL5 NPSR1

Drugs & Therapeutics for Asthma

PubMedHealth treatment related to Asthma: 63

Asthma is a long-term disease that has no cure. The goal of asthma treatment is to control the disease. Good asthma control will:Prevent chronic and troublesome symptoms, such as coughing and shortness of breathReduce your need for quick-relief medicines (see below)Help you maintain good lung functionLet you maintain your normal activity level and sleep through the nightPrevent asthma attacks that could result in an emergency room visit or hospital stayTo control asthma, partner with your doctor to manage your asthma or your child's asthma. Children aged 10 or older—and younger children who are able—should take an active role in their asthma care.Taking an active role to control your asthma involves:Working with your doctor to treat other conditions that can interfere with asthma management.Avoiding things that worsen your asthma (asthma triggers). However, one trigger you should not avoid is physical activity. Physical activity is an important part of a healthy lifestyle. Talk with your doctor about medicines that can help you stay active.Working with your doctor and other health care providers to create and follow an asthma action plan.An asthma action plan gives guidance on taking your medicines properly, avoiding asthma triggers (except physical activity), tracking your level of asthma control, responding to worsening symptoms, and seeking emergency care when needed.Asthma is treated with two types of medicines: long-term control and quick-relief medicines. Long-term control medicines help reduce airway inflammation and prevent asthma symptoms. Quick-relief, or "rescue," medicines relieve asthma symptoms that may flare up.Your initial treatment will depend on the severity of your asthma. Followup asthma treatment will depend on how well your asthma action plan is controlling your symptoms and preventing asthma attacks.Your level of asthma control can vary over time and with changes in your home, school, or work environments. These changes can alter how often you're exposed to the factors that can worsen your asthma.Your doctor may need to increase your medicine if your asthma doesn't stay under control. On the other hand, if your asthma is well controlled for several months, your doctor may decrease your medicine. These adjustments to your medicine will help you maintain the best control possible with the least amount of medicine necessary.Asthma treatment for certain groups of people—such as children, pregnant women, or those for whom exercise brings on asthma symptoms—will be adjusted to meet their special needs.

FDA approved drugs:

(show all 16)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Accolate 18 ZAFIRLUKAST AstraZeneca September 1999|October 1996
2
Advair 18 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE GlaxoSmithKline August 2000
3
Alvesco 18 CICLESONIDE Nycomed January 2008
4
Arnuity Ellipta 18 FLUTICASONE FUROATE GlaxoSmithKline August 2014
5
Azmacort 18 TRIAMCINOLONE ACETONIDE Rhone Poulenc Rorer November 1996
6
Dulera 18 FORMOTEROL FUMARATE; MOMETASONE FUROATE Merck June 2010
7
Flovent Rotadisk 18 FLUTICASONE PROPIONATE GlaxoSmithKline November 1997
8
Foradil Aerolizer 18 FORMOTEROL FUMARATE Novartis February 2001 (asthma, bronchospasm); September 2001 (COPD)
9
Metaprotereol Sulfate 18 METAPROTERENOL SULFATE Morton Grove Pharmaceuticals March 1997
10
Nucala 18 MEPOLIZUMAB GlaxoSmithKline November 2015
11
Qvar 18 BECLOMETHASONE DIPROPIONATE Ivax May 2002
12
Rayos 18 PREDNISONE Horizon Pharma July of 2012
13
Serevent 18 SALMETEROL XINAFOATE GlaxoSmithKline September 1997
14
Singulair 18 MONTELUKAST SODIUM Merck February 1998
15
Xolair 18 OMALIZUMAB Genentech June 2003
16
Zyflo 18 ZILEUTON Abbott Laboratories January 1997

Drugs for Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51333-22-3 63006 5281004
2
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10102-43-9 145068
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
4
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90566-53-3 62924
5
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 299-42-3 9294
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90-82-4 7028
7
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
8
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7487-88-9 24083
9
Ipratropium Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 60205-81-4, 22254-24-6 43232
10
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2921-57-5
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
12
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 302-25-0
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
14
Montelukast Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 158966-92-8 5281040
15
Procaterol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 72332-33-3 688561
16
Cisatracurium Approved Phase 4,Not Applicable 96946-41-7
17
Atracurium Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64228-79-1 47319
18
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 68602 5311068
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 437-38-7 3345
20
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2078-54-8 4943
21
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
22
Etomidate Approved Phase 4,Phase 3,Not Applicable 33125-97-2 667484 36339
23 tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
25
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
26
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 242138-07-4
27
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2 103577-45-3 3883
28
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2 103577-45-3, 138530-94-6 9578005
29
mometasone furoate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83919-23-7
30
Terbutaline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23031-25-6 5403
31
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-61-7 60961
32
Azelastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58581-89-8 2267
33
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6, 75614-87-8 774
34
Xylometazoline Approved, Investigational Phase 4,Phase 3,Not Applicable 526-36-3 5709
35
Capsaicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 404-86-4 1548943
36
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
37
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
38 Strawberry Approved Phase 4
39
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 26787-78-0 33613
40
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 69-65-8 453 6251
41
Cetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83881-51-0 2678
42
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 73963-72-1 2754
43
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 378-44-9 9782
44
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
45
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
46
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 84057-95-4 175805 71273
47
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 57-27-2 5288826
48
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 2180-92-9, 38396-39-3 2474
49
Ketorolac Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 66635-83-4, 74103-06-3 3826
50
Atropine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-55-8, 5908-99-6 174174

Interventional clinical trials:

(show top 50) (show all 7120)
# Name Status NCT ID Phase Drugs
1 Assessing Decision Maker Tools for Asthma: the Asthma APGAR Unknown status NCT01446315 Phase 4
2 Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home Unknown status NCT01783132 Phase 4
3 Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma. Unknown status NCT01939951 Phase 4
4 Effect of Vitamin D Supplementation on the Control of Asthma in Children at a South African Academic Hospital Unknown status NCT02053402 Phase 4 Vitamin D
5 Vitamin D for the Treatment of Severe Asthma Unknown status NCT00712205 Phase 4 Placebo;Calcitriol
6 Low Exhaled NO and ICS in Suspected Asthma Unknown status NCT02771717 Phase 4 Budesonide (Pulmicort);Placebo - dummy inhaler
7 A Pilot Study Involving an Asthma Management Program for Inner-city Early Head Start Children Unknown status NCT00624429 Phase 4 Budesonide respules
8 Inflammatory, Functional and Image Composite Measure to Define Asthma Control Unknown status NCT00597064 Phase 4 prednisone
9 Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma Unknown status NCT00500253 Phase 4
10 Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma Unknown status NCT00830505 Phase 4 fluticasone/ salmeterol;fluticasone
11 Evaluation of Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma Unknown status NCT00496574 Phase 4
12 Effects of Su-Huang Antitussive Capsule on Cough Variant Asthma Unknown status NCT01584804 Phase 4 Su-Huang antitussive capsule;Sugar pill
13 Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation Unknown status NCT02584738 Phase 4 Nebulized Magnesium Sulfate;Nebulized isotonic saline;Nebulized Salbutamol;Ipratropium bromide;Methylprednisolone or Prednisolone
14 Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma Unknown status NCT01404013 Phase 4 ICS/LABA;Montelukast;ICS/LABA and Montelukast
15 Efficacy and Safety Study of Procaterol Hydrochloride to Treat Patients With Cough Variant Asthma (CVA) Unknown status NCT01170429 Phase 4 Procaterol hydrochloride;Meptin placebo
16 Effect of Dexmedetomidine on Levels of Plasma Inflammatory Factor in Asthma Patients Undergoing General Anesthesia Unknown status NCT02289391 Phase 4 Anesthesia induction;Anesthesia maintenance;Assisted anesthesia
17 Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma Unknown status NCT01912872 Phase 4 Omalizumab;Budesonide;Formoterol
18 Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
19 Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients Unknown status NCT02934945 Phase 4 budesonide 160μg/formoterol 4.5μg
20 Effect of Specific Immunotherapy to Dust Mites in Children With Asthma Unknown status NCT00496561 Phase 4
21 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
22 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
23 Extra-fine Formoterol/Beclomethasone in Asthmatic Crisis Unknown status NCT02345993 Phase 4 Extra fine Formoterol/Beclomethasone
24 Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery Unknown status NCT02110654 Phase 4 Montelukast;mometasone furoate nasal spray
25 Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS) Unknown status NCT00867737 Phase 4 Advair HFA MDI 115/21;Symbicort 160/4.5 pMDI
26 Effect of Xolair on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
27 Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children Unknown status NCT00172341 Phase 4 Staloral TM
28 Concentrations of Salmeterol in Blood and Urine Unknown status NCT00914901 Phase 4 inhaled salmeterol
29 Terbutaline Concentrations in Blood and Urine Unknown status NCT00914797 Phase 4 inhaled and oral terbutaline
30 Efficacy of Bronchial Thermoplasty in Korean Unknown status NCT02031263 Phase 4
31 Concentrations of Formoterol in Blood and Urine Unknown status NCT00914654 Phase 4 inhaled formoterol
32 Assessment of Airway Responsiveness and Treatment Efficacy in Asthmatics Unknown status NCT02574975 Phase 4 methacholine;adenosine monophosphate;leukotriene D4;budesonide /formoterol
33 Rapid Onset Action of Salbutamol Versus Formoterol Unknown status NCT00900874 Phase 4 salbutamol;Formoterol
34 The Effect of Bronchodilator on Eosinophilic Bronchitis and Cough Variant Asthma Unknown status NCT02002754 Phase 4 Bambuterol Hydrochloride tablets
35 mRNA Expression as a Biomarker of Omalizumab Response Unknown status NCT01584687 Phase 4
36 A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control Unknown status NCT00385359 Phase 4 Albuterol
37 Treatment of Acute Asthma in ER With Combination of Systemic Steroids and Inhaled Steroids Unknown status NCT00397267 Phase 4 inhalation of corticosteroids
38 Efficacy and Safety of LAIS® Mites Sublingual Tablets Unknown status NCT02277483 Phase 4 LAIS®
39 4"S" - Seasonal Symptoms Suppression Study Unknown status NCT02557269 Phase 4 Xylometazoline - intranasal application;Azelastine - intranasal application;Mometasone furoate - intranasal application;Hydroxyl-propyl-methyl cellulose powder - intranasal application;Bilastine 20 mg;Prednisolone 5 mg
40 Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4 Sinol or Sinol-M nasal spray
41 POLlinosis and Exhaled Breath Temperature Unknown status NCT01785394 Phase 4 5 grass allergen extract
42 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
43 Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4 Control
44 Preterm Infant Inhaled Albuterol Dosing Unknown status NCT02447250 Phase 4 Varied albuterol dose response
45 Bronchiolitis All-study, SE-Norway Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
46 Montelukast for Persistent Cough in Young People and Adults Unknown status NCT01279668 Phase 4 Montelukast;Placebo
47 Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function Unknown status NCT01466712 Phase 4 Tiotropium + formoterol/beclometasone;tiotropium + placebo
48 Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep Unknown status NCT00731770 Phase 4 fluticasone/salmeterol 250/50;placebo
49 Airway Effects of Tiotropium in Patients With COPD Unknown status NCT02683668 Phase 4
50 Can we Help People With the Oral Allergy Syndrome Eat Fresh Fruit? Unknown status NCT01431859 Phase 4

Search NIH Clinical Center for Asthma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Asthma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Asthma:
Bone marrow-derived mesenchymal stem cells for severe refractory asthma
Embryonic/Adult Cultured Cells Related to Asthma:
Mouse bone marrow-derived mesenchymal stem cells (family) PMIDs: 21653527 20801416

Cochrane evidence based reviews: asthma

Genetic Tests for Asthma

Genetic tests related to Asthma:

# Genetic test Affiliating Genes
1 Asthma, Susceptibility to 29 ADRB2 ALOX5 CCL11 HLA-G HNMT IL13 MUC7 PLA2G7 SCGB3A2 TNF
2 Asthma 29

Anatomical Context for Asthma

MalaCards organs/tissues related to Asthma:

41
Lung, Testes, T Cells, Neutrophil, Smooth Muscle, Heart, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Asthma:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Trachea Airway Smooth Muscle Cells Affected by disease, potential therapeutic candidate

Publications for Asthma

Articles related to Asthma:

(show top 50) (show all 9550)
# Title Authors Year
1
Obesity and adiposity indicators in asthma and allergic rhinitis in children. ( 30507714 )
2019
2
Evaluating the role of mindfulness in terms of asthma-related outcomes and depression and anxiety symptoms among individuals with asthma. ( 30286606 )
2019
3
Association of major California freight railyards with asthma-related pediatric emergency department hospital visits. ( 30533348 )
2019
4
Genetic variants in RORA are associated with asthma and allergy markers in an admixed population. ( 30539779 )
2019
5
SPECT Ventilation Imaging in Asthma. ( 30545510 )
2019
6
Clinical Implications of Single Nucleotide Polymorphisms in Diagnosis of Asthma and its Subtypes. ( 30554485 )
2019
7
Occupational rhinitis, asthma, and contact urticaria from IgE-mediated allergy to pork. ( 30474282 )
2019
8
Biomarkers for Recurrent Wheezing and Asthma in Preschool Children. ( 30479074 )
2019
9
Characteristics of Adult Severe Refractory Asthma in Korea Analyzed From the Severe Asthma Registry. ( 30479076 )
2019
10
Association Between Epithelial Cytokines and Clinical Phenotypes of Elderly Asthma. ( 30479079 )
2019
11
Different Biological Pathways Are Up-regulated in the Elderly With Asthma: Sputum Transcriptomic Analysis. ( 30479081 )
2019
12
Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab. ( 30479771 )
2019
13
Asthma, obesity and targeted interventions: an update. ( 30480592 )
2019
14
The impact of adenotonsillectomy on pediatric asthma. ( 30489041 )
2019
15
Evaluation of expiratory capacity with severe asthma following bronchial thermoplasty. ( 30510765 )
2019
16
Bronchiectasis and asthma: a dangerous liaison? ( 30516546 )
2019
17
Innate lymphoid cells in asthma: pathophysiological insights from murine models to human asthma phenotypes. ( 30516548 )
2019
18
Maternal vitamin D and E intakes in pregnancy and asthma to age 15 years: A cohort study. ( 30426718 )
2019
19
Oral corticosteroid-dependent asthma: current knowledge and future needs. ( 30461530 )
2019
20
Bronchiectasis in severe asthma: a distinct phenotype? ( 30461531 )
2019
21
The many faces of asthma-chronic obstructive pulmonary disease overlap. ( 30461532 )
2019
22
Wrong inhalation technique is associated to poor asthma clinical outcomes. Is there room for improvement? ( 30461535 )
2019
23
Beta2-adrenergic receptor variants in children and adolescents with bronchial asthma. ( 30468638 )
2019
24
Is residential ambient air limonene associated with asthma? Findings from the Canadian Health Measures Survey. ( 30469291 )
2019
25
Obesity and adult asthma: diagnostic and management challenges. ( 30394901 )
2019
26
Role of microRNAs and exosomes in asthma. ( 30394902 )
2019
27
Maternal attachment avoidance is linked to youth diurnal cortisol slopes in children with asthma. ( 30406724 )
2019
28
Recent developments in asthma in pregnancy. ( 30407268 )
2019
29
Analysis of FOXO3a Gene Polymorphism Associated with Asthma. ( 30414161 )
2019
30
Targeting lipid mediators in asthma: time for reappraisal. ( 30422894 )
2019
31
New insights in neutrophilic asthma. ( 30422895 )
2019
32
Unravelling the complexity of tissue inflammation in uncontrolled and severe asthma. ( 30422896 )
2019
33
Strategies to prevent exacerbations of childhood asthma. ( 30422897 )
2019
34
Long-term exposure to ambient fine particles associated with asthma: A cross-sectional study among older adults in six low- and middle-income countries. ( 30316099 )
2019
35
Occupational asthma: clinical phenotypes, biomarkers, and management. ( 30320613 )
2019
36
Role of genomics in asthma exacerbations. ( 30334825 )
2019
37
Obesity and childhood asthma. ( 30334826 )
2019
38
Respiratory symptoms, asthma and levels of fractional exhaled nitric oxide in schoolchildren in the industrial areas of Estonia. ( 30195132 )
2019
39
Federal Weatherization and Health Education Team up: Process Evaluation of a New Strategy to Improve Health Equity for People With Asthma and Chronic Obstructive Pulmonary Disease. ( 29595574 )
2019
40
Eicosapentaenoic Acid Enhances the Effects of Mesenchymal Stromal Cell Therapy in Experimental Allergic Asthma. ( 29881388 )
2018
41
The effects of bone marrow-derived mesenchymal stem cells on ovalbumin-induced allergic asthma and cytokine responses in mice. ( 29922428 )
2018
42
Economic Burden of Pediatric Asthma: Annual Cost of Disease in Iran. ( 29445636 )
2018
43
Lactic Acidosis and Asthma Exacerbation. ( 29801682 )
2018
44
Canadian genome-wide association study and meta-analysis confirm HLA as a risk factor for peanut allergy independent of asthma. ( 29325868 )
2018
45
Altered expression of IL-18 binding protein and IL-18 receptor in basophils and mast cells of asthma patients. ( 29505668 )
2018
46
Hair analysis to monitor adherence to prescribed chronic inhaler drug therapy in patients with asthma or COPD. ( 29981458 )
2018
47
Association Between Obesity and Acute Severity Among Patients Hospitalized for Asthma Exacerbation. ( 29452277 )
2018
48
Eosinophil-derived exosomes contribute to asthma remodelling by activating structural lung cells. ( 29451337 )
2018
49
Advances and Evolving Concepts in Allergic Asthma. ( 29427987 )
2018
50
Expansion of a CD26<sup>low</sup>effector TH subset and reduction of circulating levels of sCD26 in stable allergic asthma in adults. ( 29297467 )
2018